Genelux (GNLX) Current Deferred Revenue (2022)
Genelux (GNLX) posted Current Deferred Revenue of $170000.0 for Q4 2022.
Powered by 
Analysis
Genelux (GNLX) Current Deferred Revenue (2022) Analysis & Trends
Genelux has reported Current Deferred Revenue for 1 years, with the latest figure at $170000.0 in Q4 2022.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $170000.0 in Q4 2022; TTM through Dec 2022 was $170000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $170000.0, changed N/A from the prior year.
- Current Deferred Revenue was $170000.0 for Q4 2022 at Genelux.
- The five-year high for Current Deferred Revenue was $170000.0 in Q4 2022, with the low at $170000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - |